Coherus Oncology Q4 Sales Miss Estimates by $1.15M, Adjusted Net Income Also Falls Short
summarizeSummary
Coherus Oncology reported fourth-quarter sales of $12.748 million, significantly missing the IBES estimate of $13.9 million. The company also posted an adjusted net income of -$40.42 million, which was worse than analyst expectations of -$35.1 million. This dual miss on both top-line revenue and bottom-line profitability indicates weaker-than-anticipated financial performance for the quarter. For a company of Coherus Oncology's size, these material misses are likely to exert downward pressure on the stock as traders react to the unexpected shortfall. Investors will now focus on any accompanying management commentary regarding the reasons for the miss and the outlook for the upcoming periods.
At the time of this announcement, CHRS was trading at $1.80 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $288.5M. The 52-week trading range was $0.71 to $2.62. This news item was assessed with negative market sentiment and an importance score of 8 out of 10. Source: Reuters.